BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25856827)

  • 1. Resolution of exudative changes refractory to ranibizumab after aflibercept injections at the margin of inferior staphyloma in tilted disc syndrome.
    Hirano Y; Yasukawa T; Tsukada A; Yokoyama S; Ito Y; Nakazawa Y
    Ophthalmic Surg Lasers Imaging Retina; 2015 Mar; 46(3):384-6. PubMed ID: 25856827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
    Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
    Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration.
    Schmidt-Erfurth U; Waldstein SM; Deak GG; Kundi M; Simader C
    Ophthalmology; 2015 Apr; 122(4):822-32. PubMed ID: 25578255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of macular serous neuroretinal detachment in tilted disk syndrome: report of 3 cases.
    Donati MC; Miele A; Abbruzzese G; Giuntoli M; Giansanti F; Menchini U
    Eur J Ophthalmol; 2013; 23(2):267-70. PubMed ID: 23225087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB: Time Course and Drug Effects.
    de Massougnes S; Dirani A; Ambresin A; Decugis D; Marchionno L; Mantel I
    Retina; 2016 May; 36(5):881-8. PubMed ID: 27115852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative OCT subanalysis of eyes with choroidal neovascularization switched from multiple injections of bevacizumab or ranibizumab to intravitreal aflibercept.
    Hariri A; Diniz B; Fou LV; Lam LA; Nittala MG; Sadda SR
    Ophthalmic Surg Lasers Imaging Retina; 2015 Feb; 46(2):195-200. PubMed ID: 25707044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy.
    Hosokawa M; Shiraga F; Yamashita A; Shiragami C; Ono A; Shirakata Y; Kimura S; Shiode Y; Kawata T; Hosogi M; Fujiwara A; Morizane Y
    Br J Ophthalmol; 2015 Aug; 99(8):1087-91. PubMed ID: 25712826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.
    Cho H; Shah CP; Weber M; Heier JS
    Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AFLIBERCEPT FOR THE TREATMENT OF RETINAL PIGMENT EPITHELIAL DETACHMENTS.
    He L; Silva RA; Moshfeghi DM; Blumenkranz MS; Leng T
    Retina; 2016 Mar; 36(3):492-8. PubMed ID: 26398694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal ranibizumab for pigment epithelium detachment with subfoveal occult choroidal neovascularization: a prospective 24-month case series.
    Parodi MB; Iacono P; Papayannis A; Kontadakis SD; Cascavilla M; Pierro L; Gagliardi M; Bandello F
    Am J Ophthalmol; 2013 Jan; 155(1):103-108.e2. PubMed ID: 23022164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging characteristics of neovascular pigment epithelial detachments and their response to anti-vascular endothelial growth factor therapy.
    Punjabi OS; Huang J; Rodriguez L; Lyon AT; Jampol LM; Mirza RG
    Br J Ophthalmol; 2013 Aug; 97(8):1024-31. PubMed ID: 23759437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose ranibizumab therapy for vascularized pigment epithelial detachment.
    Chan CK; Abraham P; Sarraf D
    Eye (Lond); 2012 Jun; 26(6):882-5. PubMed ID: 22576827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degeneration.
    Broadhead GK; Hong T; Zhu M; Li H; Schlub TE; Wijeyakumar W; Chang AA
    Retina; 2015 May; 35(5):975-81. PubMed ID: 25627086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
    Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
    J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of Change in Pigment Epithelial Detachment Volume and Morphology After Transition to Intravitreal Aflibercept in Eyes With Recalcitrant Neovascular AMD: 18-Month Results.
    Kanesa-Thasan A; Grewal DS; Gill MK; Lyon AT; Mirza RG
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):638-41. PubMed ID: 26114844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
    Kang HM; Kwon HJ; Yi JH; Lee CS; Lee SC
    Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab.
    Saito M; Kano M; Itagaki K; Oguchi Y; Sekiryu T
    Retina; 2014 Nov; 34(11):2192-201. PubMed ID: 25077530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resolution of persistent pigment epithelial detachment secondary to polypoidal choroidal vasculopathy in response to Aflibercept.
    Cheung CM; Mohla A; Wong TY
    Eye (Lond); 2014 Sep; 28(9):1148-9. PubMed ID: 24833182
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.